News

PharmiWeb15m
The Scottish Medicines Consortium (SMC) has announced that following a Fast Track Resubmission by Eisai, Leqembi® (lecanemab) has not been recommended for use in the National ...
HATFIELD, HERTFORDSHIRE, UNITED KINGDOM (UK), and MAIDENHEAD, UK, 7 JULY 2025 – Eisai Europe Ltd. and Biogen Idec Ltd. announced today that the Scottish Medicines Consortium (SMC) has not recommended ...
PharmiWeb39m
Ciloa secures €6.5 million government funding from France 2030 ‘Innovation in biotherapies and biomanufacturing’ to develop drug candidate for treatment of obesity and ...
DIADEME’ project awarded €6.5 million in government funding via France 2030, enabling Ciloa to advance development of its bio-drug APN-sEV (Adiponectin associated with exosomes), the world’s only ...
PharmiWeb44m
Inhaled Antifungals Market to Reach $450 Million by 2025, Fueled by Rising Adoption in Invasive Fungal Infections
Inhaled Antifungals Market to Reach $450 Million by 2025, Fueled by Rising Adoption in Invasive Fungal Infections The global inhaled antifungals market is projected to reach $450 million in 2025, ...
PharmiWeb55m
MMJ International Redefines Medical Cannabis with First Plant-Based Drug for a Rare Neurological Disease
MMJ-001 Marks a Pharmaceutical First in Cannabis Medicine with FDA-Grade Formulation for a Devastating Neurological Disorder while awaiting final FDA approval for use in clinical trials. WASHINGTON, D ...